Improved adherence to statin treatment and differences in results between men and women after pictorial risk communication—a sub-study of the VIPVIZA RCT
Open Access
- 29 April 2024
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 80 (8) , 1209-1218
Abstract
Background: People with intermediate CVD risk constitute most of the population. Within this group, the proportion of events is lower compared to the high-risk group, but they contribute with the largest absolute number of events. Atherosclerosis is a dynamic process and progression can be slowed or even reversed with medication and lifestyle changes, but adherence to prescribed treatment is crucial. Aim: To investigate the long-term effects of interventions with pictorial risk communication of cardiovascular (CVD) risk on average adherence in a group of statin users. Compare response in adherence over time between men and women after intervention. Methods: Participants on active statin treatment were followed up to 5 years after being randomly assigned to an intervention program aimed at raising CVD risk awareness among participants and their physicians. Merging prescribed medication databases with VIPVIZA study to study adherence over time. A moving average adherence was used to compare groups. Results: Generally, the average adherence to statins among the 512 participants was high. Men had a higher average adherence over time, while women had a sharper increase in adherence in conjuncture with the intervention program. Conclusions: Both men and women were receptive to pictorial information regarding CVD risk, but the intervention effect was more pronounced in women. Sex differences are important when considering risk communication strategies. Periodically repeating the intervention was beneficial for maintaining the intervention effect over time. Trial registration: The VIPVIZA study is registered with ClinicalTrials.gov, May 8, 2013, number NCT01849575.Keywords
Funding Information
- Vetenskapsrådet (521-2013-2708)
- Hjärt-Lungfonden (20150369)
- Umea University
This publication has 30 references indexed in Scilit:
- Does a multi-component intervention including pictorial risk communication about subclinical atherosclerosis improve perceptions of cardiovascular disease risk without deteriorating efficacy beliefs?Social Science & Medicine, 2023
- What CVD risk factors predict self-perceived risk of having a myocardial infarction? A cross-sectional studyInternational Journal of Cardiology Cardiovascular Risk and Prevention, 2022
- Prescription of Lipid-Lowering and Antihypertensive Drugs Following Pictorial Information About Subclinical AtherosclerosisJAMA Network Open, 2021
- Differences between men and women in the use of preventive medications following a major cardiovascular event: Australian prospective cohort studyPreventive Medicine Reports, 2021
- The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trialAmerican Journal of Preventive Cardiology, 2021
- Increased knowledge makes a difference! – general practitioners’ experiences of pictorial information about subclinical atherosclerosis for primary prevention: an interview study from the VIPVIZA trialScandinavian Journal of Primary Health Care, 2021
- Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: Need for customisation strategiesPharmacological Research, 2020
- Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trialThe Lancet, 2019
- Statin Adherence: Does Gender Matter?Current Atherosclerosis Reports, 2016
- The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six monthsPharmacoepidemiology and Drug Safety, 2006